Claude

What's Next

Cigna Group's catalyst calendar over the next 3-6 months is anchored by earnings, buyback execution, and the early innings of the rebate-free PBM transition.

No Results

Next Earnings

Late Apr 2026

Q1 2026 Est. EPS

$7.20

FY2026 Est. Adj EPS

$32.50

What the market will watch most closely: The medical care ratio. CI has posted MCR increases for three consecutive years (78.8% to 84.4%). If Q1 2026 shows stabilization or reversal, the stock could re-rate meaningfully. If MCR continues rising toward 86%+, Cigna Healthcare's profit contribution becomes negligible and the stock becomes a pure PBM play at a PBM multiple – which is lower than the current price implies.

The secondary catalyst is Evernorth margin disclosure. Pre-tax margins fell from 4.2% to 3.1% over two years. The market needs to see the floor. The rebate-free model transition adds uncertainty, but management's $500M+ Strategic Optimization Program savings provide a partial offset.

There is no obvious binary catalyst in the next 90 days. This is a grind-higher story dependent on continued EPS delivery and buyback execution, not a single event.

The Verdict

Verdict

Conditional Buy

Current Price

$278

Prob-Weighted Value

$316

Implied Upside

13.7%

Asymmetry Ratio

1.7

Position Size

3-4% of portfolio

**Conditional Buy at $278.** CI is priced for stagnation (8.9x forward earnings, 11% FCF yield) while delivering 10% adjusted EPS growth. The gap between earnings trajectory and valuation is real, but the conditions for re-rating are specific and not yet confirmed. Buy only if you can hold through 2-3 quarters of MCR and margin data.

Bull / Base / Bear Scenarios

No Results

**Bull ($370, 25% probability):** MCR reverses toward 83% as IFP repricing takes hold. Evernorth demonstrates margin stability at 3%+ while the rebate-free model wins new clients in the 2027 selling season. At $33 EPS and 11x forward, the stock reaches $363-370. Buybacks at these low prices supercharge per-share economics. This scenario requires MCR improvement AND Evernorth margin stabilization -- both are plausible but not yet confirmed.

**Base ($310, 50% probability):** The EPS machine keeps grinding. Adj EPS reaches ~$33 via 8% organic growth plus 3-4% from buybacks. MCR drifts modestly higher but Cigna Healthcare remains profitable. Evernorth margin stabilizes near 3%. The stock trades at 9-9.5x forward -- still cheap but no catalyst forces a re-rating. Total return of ~13% including dividends over the next 12 months.

**Bear ($220, 25% probability):** Medical costs accelerate sector-wide. PBM reform legislation passes, compressing Evernorth spreads. MCR exceeds 87%, forcing CI to exit more insured lines. Evernorth margin dips below 2.5%, putting the Express Scripts acquisition economics in doubt. At $30 EPS and 7x forward, the stock falls to $210-220. This scenario requires multiple things to go wrong simultaneously.

The Math

Probability-weighted value: $316 = (0.25 x $370) + (0.50 x $310) + (0.25 x $220) = $92.50 + $155.00 + $55.00 + $13.50 in dividends.

Asymmetry ratio: 1.7x. Bull upside of $92/share vs. bear downside of $58/share. This is modest asymmetry – not compelling enough for aggressive sizing, but positive enough to justify a position.

Conditions for Success

No Results

Failure Triggers

No Results

What the Market May Be Missing

The market is pricing CI as a managed care company caught in the sector-wide MCR crisis. But 86% of CI's revenue and 73% of its pre-tax income comes from Evernorth, which is a pharmacy services business with fundamentally different economics than health insurance. The managed care de-rating has pulled CI down with its peers, but CI's earnings stability through the sector downturn has been better than the stock price suggests.

The specific disconnect: adjusted EPS has grown every year since FY2019 and hit an all-time high in FY2025, yet the stock trades at a 9.3x trailing P/E – the lowest implied multiple in over a decade. At its own 5-year average multiple of ~11.5x, CI would trade at $343. The question is whether there is a catalyst to close this gap.

The honest answer: there is no single catalyst. This is a compounding story – EPS grows 8-10% annually, buybacks add 3-4% to per-share growth, dividends yield 2.2%. Total shareholder return of 13-16% annually is achievable even without multiple expansion. The downside is that the stock could stay cheap for years if the managed care sector overhang persists.

Position sizing: 3-4% of portfolio. The asymmetry is positive but not extreme. The business quality is high (consistent FCF, locked-in contracts, shrinking share count), but the path risk is real (MCR uncertainty, regulatory overhang, margin compression). This is a position to build over 2-3 quarters, not a conviction bet to take all at once.

LEAPS / Options

January 2028 LEAPS are available with reasonable liquidity. The 21-month duration captures at least 6 earnings reports and the critical MCR stabilization window.

Stock Price

$277.56

Expiration

2028-01-21

Months to Expiry

Implied Volatility

31.7%

No Results

Payoff Analysis by Scenario

No Results

LEAPS Verdict

No Results

**Preferred contract: $240 strike, Jan 2028 LEAPS at ~$73 mid.** This is the only contract with a positive expected value across all three probability-weighted scenarios. The 0.76 delta provides meaningful equity exposure, the $313 breakeven requires only 13% stock appreciation over 21 months (roughly in line with the base case total return), and the 515 open interest suggests adequate liquidity for institutional-sized positions. Max loss is $73/contract vs. $278/share for equity -- a 74% capital reduction for ~76% of the upside exposure.

**Avoid $300+ strikes.** These require 24%+ appreciation just to break even and have negative probability-weighted expected values. The asymmetry that makes CI interesting as an equity position does not extend to OTM LEAPS -- the payoff structure requires too much multiple expansion within the timeframe.

Overall options verdict: LEAPS are a viable alternative to equity for investors who want to limit capital at risk while maintaining exposure to CI's compounding thesis. The $240 strike is the standout – it functions as a leveraged equity substitute with defined downside. Use LEAPS for 30-40% of intended CI exposure, holding the remainder in equity for dividend capture and unlimited duration.